01P , ' AUS 122	The second secon	
TRADEM!	PATENT Docket No. 300622002021	#7/8
	CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"	08.27.02
٦)	I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:	00.27.02
	Assistant Commissioner for Patents, Washington, D.C. 20231, on August <u>1</u> , 2002.	
k.	Jan A. Jam	
	Garee A. Haney	

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Bryan JULIEN

Serial No.: 09/942,025

Filing Date: August 28, 2001

For: POLYKETIDE SYNTHASE GENE FROM SORANGIUM CELLULOSUM Examiner: To Be Assigned

Group Art Unit: 1652

RECEIVED

AUG 1 4 2002

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents Nos. 9, 10 and 18 are included herewith. Copies of all other documents were previously submitted in an Information Disclosure Statement and/or Office Action, directed to the related application Serial Numbers 09/010,809, filed January 22, 1998, now United States Patent Number 6,090,601, and 09/144,085, filed August 31, 1998, now United States Patent Number 6,280,999, and, accordingly, copies are not included herewith. This protocol conforms

with 37 C.F.R. §1.98(d) and M.P.E.P. 609(A)(2). The Examiner is requested to make these documents of record in the application.

This application is a Continuation-In-Part of United States Serail Number 09/144,085, filed August 31, 1998, now United States Patent Number 6,280,999, which is a Continuation-In-Part of United States Serail Number 09/010,809, filed January 22, 1998, now United States Patent Number 6,090,601, and claims the benefit of the filing date of United States Provisonal Application Number 60/271,245, filed February 15, 2001.

This Information Disclosure Statement is submitted:

.

٩,

A

With the application; accordingly, no fee or separate requirements are required.

- \square Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
 - After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

A fee is required. A check in the amount of * is enclosed.



A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.

- After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449,

indicating that the information has been considered and made of record herein.

2

Serial No. 09/942,025 Docket No. 300622002021 The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing <u>300622002021</u>. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: August <u>7</u>, 2002

Ą.

Respectfully submitted,

Registration No. P-51,979

Morrison & Foerster LLP

3811 Valley Centre Drive Suite 500 San Diego, California 92130-2332 Telephone: (858) 720-7912 Facsimile: (858) 720-5125

3

Serial No. 09/942,025 Docket No. 300622002021

		E			Docket Number 3006	22002021	Application Nu		25 et 1 of 2
Form PTO-1449				-	Docket Number 300622002021 Application Number 09/942,025				
INFOR)N DISCLO AN APPLIO	SURE CITATION	N	Applicant	Bria	n JULIEN		
(Use several sheets if necessary)					Filing Date August 2	8, 2001	Group Art Unit 1652		
					Mailing Date August	7_, 2002			
			U.S. PA	ATENT	DOCUMENT	ſS			
Examiner Initials	Ref. No.	Date	Document No.		Name	Class	Subclass	Filing I Appro	
	1.	11/1985	4,551,433	DeBo	er	435	253		
	2.	10/1989	4,874,748	Katz,	et al.	514	29	RECE	IVEL
	3.	11/1991	5,063,155	Cox,	et al.	435	76		4 2002
	4.	03/1992	5,098,837	Beck	mann, et al.	435	172.3		
	5.	05/1992	5,116,756	Dumo	ont, et al.	435	TE	CH CENTI	ER 1600/2
	6.	09/1992	5,149,639	Katz,	et al.	435	76		
	7.	09/1997	5,672,491	Khos	la, et al.	435			
	8.	01/1998	5,712,146	Khos	la, et al.	435			
	9.	07/2000	6,090,601	Gusta	afsson et al.	435	183		
• · · · · • • • • • • • • • • • •	10.	08/2001	6,280,999	Gusta	afsson et al.	435	252.3		
Examiner	Ref.	Date	FOREIGN Document No.	N PATI	ENT DOCUM Country	ENTS Class	Subclass		slation
Initials	No.				. <u></u>			YES	
	11.	08/1997	EP 0 791 655	Euro					N/A
	12.	07/1993	WO 93/13663	PCT					N/A
	13.	03/1995	WO 95/08548	PCT					N/A
	14.	12/1996	WO 96/40968	PCT					N/A
	15.	01/1997	WO 97/02358	PCT					
	16.	06/1997	WO 97/22711	PCT	- IN				
	17.	06/1998	WO 98/27203	PCT					N/A
	18.	04/2000	WO 00/22139	PCT				<u> </u>	
			OT	HER D	OCUMENTS	(inc	luding author, title,	Date, Pertinen	nt Pages, Etc.,
	Ref. No.	Title							
Examiner Initials	19.	Aigle et a	l., Microbiology 142	2:2815-2	2824 (1996)				<u></u> -
					DATE C	ONSIDERED:		,,,,	- <u></u>
	INER:				1				

 \mathbb{R}_{1}

•		AUG 1 2 200		PTO/SB/08 (2-92) Sheet 2 of 2			
Form PTO-	1449	A AND AND A	Docket Number 300622002021	Application Number 09/942,025			
Form PTO-1449 INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Brian JULIEN				
	(U:	se several sheets if necessary)	Filing Date August 28, 2001	Group Art Unit 1652			
<u></u>			Mailing Date August 7, 2002				
Examiner	Ref.	OTHER I Title	DOCUMENTS (inclu	uding author, title, Date, Pertinent Pages, Etc.,			
Initials	No.						
	20.	Bollag et al., Cancer Research 55:2325-2333 (1995)					
	21.	Caffrey et al, <u>FEBS Letters</u> 304:205 (1992) AUG 1 4 2002					
	22.	Cortes et al., <u>Nature</u> 348:176-178 (1990)					
	23.	Dalbie-McFarland et al., Proc. Natl. Acad. Sci. USA 79:6409-6413 (1982) TECH CENTER 1600/29					
	24.	Fu et al, Biochemistry 33:9321-9326 (1994) Geisselsoder et al., BioTechniques 5:786-791 (1987)					
	25.	Gersselsoder et al., <u>Biorechniques</u> 5.780-791 (1987) Gerth et al., <u>Journal of Antibiotics</u> 49:560-563 (1996)					
	26.	Jay et al., <u>J. Bio. Chem</u> . 259:6311-6317 (1984)					
	27.	Kunkel, <u>Proc. Natl. Acad. Sci. USA</u> 82:488-492 (1985)					
	28. 29.	McDaniel <i>et al.</i> , <u>Science</u> 262:1546-1550 (1993)					
	30.	Motamedi <i>et al.</i> , "Structural organization of a multifunctional polyketide synthase involved in the biosynthesis of the macrolide immunosuppressant FK506", Eur. J. Biochem., 244, pp.74-80.					
	31.	Rohr, Angew. Chem. Int. Ed. Engl. 34(8):881-888 (1995)					
	32.	Schupp et al., Journal of Bacteriology 177:3673-3679					
	33.	Schwecke <i>et al.</i> , "The biosynthetic <u>Proc. Nat'l Acad. Sci. USA 92</u> (Aug Scottie <i>et al.</i> , <u>Gene</u> 130:65-71 (199)	g. 1995), pp. 7839-7843.	immunosuppressant rapamycin",			

EXAMINER:	DATE CONSIDERED:
EXAMINER: Initial if citation considered, v	whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in copy of this form with next communication to applicant.
contormance and not considered. merade a	Patent and Trademark Office; U.S. DEPARTMENT OF COMME